XTX Topco Ltd Sells 2,858 Shares of Eton Pharmaceuticals, Inc. (NASDAQ:ETON)

XTX Topco Ltd cut its holdings in Eton Pharmaceuticals, Inc. (NASDAQ:ETON) by 19.5% during the first quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 11,797 shares of the company’s stock after selling 2,858 shares during the quarter. XTX Topco Ltd’s holdings in Eton Pharmaceuticals were worth $153,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also recently bought and sold shares of the business. JPMorgan Chase & Co. raised its holdings in Eton Pharmaceuticals by 7,086.9% in the fourth quarter. JPMorgan Chase & Co. now owns 51,961 shares of the company’s stock worth $692,000 after purchasing an additional 51,238 shares during the period. Envestnet Asset Management Inc. acquired a new stake in Eton Pharmaceuticals in the fourth quarter worth $236,000. Renaissance Technologies LLC raised its holdings in Eton Pharmaceuticals by 131.5% in the fourth quarter. Renaissance Technologies LLC now owns 193,100 shares of the company’s stock worth $2,572,000 after purchasing an additional 109,700 shares during the period. Raymond James Financial Inc. acquired a new stake in Eton Pharmaceuticals in the fourth quarter worth $147,000. Finally, Barclays PLC acquired a new stake in Eton Pharmaceuticals in the fourth quarter worth $731,000. 27.86% of the stock is owned by institutional investors.

Eton Pharmaceuticals Trading Down 1.2%

Shares of NASDAQ:ETON opened at $17.12 on Thursday. Eton Pharmaceuticals, Inc. has a 12 month low of $3.75 and a 12 month high of $21.48. The company has a quick ratio of 1.16, a current ratio of 1.77 and a debt-to-equity ratio of 1.14. The company’s fifty day simple moving average is $14.84 and its 200 day simple moving average is $15.49. The firm has a market cap of $459.16 million, a price-to-earnings ratio of -107.00 and a beta of 1.13.

Eton Pharmaceuticals (NASDAQ:ETON) last issued its quarterly earnings data on Thursday, August 7th. The company reported ($0.10) EPS for the quarter, missing analysts’ consensus estimates of ($0.01) by ($0.09). Eton Pharmaceuticals had a negative return on equity of 0.73% and a negative net margin of 7.10%. The company had revenue of $18.93 million for the quarter, compared to analyst estimates of $16.71 million. As a group, research analysts forecast that Eton Pharmaceuticals, Inc. will post -0.14 EPS for the current fiscal year.

Insider Activity at Eton Pharmaceuticals

In other Eton Pharmaceuticals news, insider David Krempa sold 10,223 shares of Eton Pharmaceuticals stock in a transaction on Monday, June 16th. The shares were sold at an average price of $14.73, for a total value of $150,584.79. Following the sale, the insider directly owned 612,646 shares in the company, valued at approximately $9,024,275.58. The trade was a 1.64% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Insiders have sold 34,000 shares of company stock worth $504,318 in the last quarter. Company insiders own 16.03% of the company’s stock.

Wall Street Analysts Forecast Growth

Several equities research analysts have weighed in on the stock. Craig Hallum increased their target price on shares of Eton Pharmaceuticals from $26.00 to $28.00 and gave the stock a “buy” rating in a report on Wednesday, May 14th. HC Wainwright reiterated a “buy” rating and issued a $35.00 target price (up from $33.00) on shares of Eton Pharmaceuticals in a report on Thursday, May 29th. B. Riley reiterated a “buy” rating and issued a $26.00 target price (up from $24.00) on shares of Eton Pharmaceuticals in a report on Friday, May 16th. Finally, Wall Street Zen lowered shares of Eton Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Saturday, August 9th.

Eton Pharmaceuticals Profile

Eton Pharmaceuticals, Inc, a specialty pharmaceutical company, focuses on developing, acquiring, and commercializing pharmaceutical products for rare diseases. The company offers ALKINDI SPRINKLE, a replacement therapy for adrenocortical insufficiency in children under 17 years of age; Carglumic Acid for the treatment of acute and chronic hyperammonemia due to N-acetylglutamate Synthase deficiency; Betaine Anhydrous for the treatment of homocystinuria; and Nitisinone for the treatment of tyrosinemia type 1.